Brokerages Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) PT at $28.67

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $28.6667.

A number of brokerages recently issued reports on KYTX. Wells Fargo & Company lifted their price target on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen raised shares of Kyverna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th.

Institutional Trading of Kyverna Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. bought a new stake in shares of Kyverna Therapeutics in the 4th quarter valued at approximately $15,667,000. AIGH Capital Management LLC acquired a new stake in shares of Kyverna Therapeutics during the 4th quarter valued at approximately $14,100,000. Balyasny Asset Management L.P. bought a new position in Kyverna Therapeutics during the fourth quarter worth $9,220,000. Propel Bio Management LLC bought a new position in Kyverna Therapeutics during the fourth quarter worth $6,267,000. Finally, Alyeska Investment Group L.P. acquired a new position in Kyverna Therapeutics in the fourth quarter worth $5,640,000. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Price Performance

Shares of KYTX opened at $8.54 on Tuesday. The business’s 50 day moving average is $8.37 and its two-hundred day moving average is $7.41. Kyverna Therapeutics has a 52-week low of $1.78 and a 52-week high of $13.67. The firm has a market cap of $374.05 million, a price-to-earnings ratio of -2.29 and a beta of 3.32.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.